RxDoctor Payments Data

Jennifer Palmer, APRN

Nurse Practitioner · Naples, FLNPI 1245587112

Payments from drug & device makers

$5,065in general payments, 2019–2025

Across 179 payments — averaging $28.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Axonics, Inc.$2K
  • Astellas Pharma US Inc$547
  • Sumitomo Pharma America, Inc.$431
  • AbbVie$341
  • Coloplast$306
  • Endo Pharmaceuticals Inc.$297
  • plus $2K from 25 others

What the payments were for

  • Travel & lodging$65913%
  • Food & beverage$4,15682%
  • Education$2505%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,065 in reported general payments places this provider in the 90th percentile of 8,290 nurse practitioner providers in Florida.

See all nurse practitioner providers in Florida

Medicare billing

Part B allowed, 2024
$129,940
Medicare patients
433
Services billed
13,729

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron177$213,091
MyrbetriqMirabegron177$192,880
ErleadaApalutamide13$188,928
OrgovyxRelugolix23$60,724
Testosterone52$25,239
Mirabegron ErMirabegron19$13,577
Tadalafil127$10,577
Dutasteride219$8,191
Tamsulosin Hcl421$7,361
Silodosin41$5,577
Alfuzosin Hcl ErAlfuzosin Hcl188$4,833
Solifenacin Succinate107$4,745
Testosterone Cypionate41$3,313
Finasteride150$3,302
Potassium Citrate ErPotassium Citrate11$3,200

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa, Orgovyx$431$273,815200 claims
Astellas Pharma US IncMyrbetriq$547$192,880177 claims
Johnson & JohnsonErleada$135$188,92813 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,290 nurse practitioner providers in Florida.

Other nurse practitioner in Naples

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →